216 related articles for article (PubMed ID: 21923736)
61. Lipids modulate ligand binding to sulphonylurea receptors.
Klein A; Lichtenberg J; Stephan D; Quast U
Br J Pharmacol; 2005 Aug; 145(7):907-15. PubMed ID: 15895108
[TBL] [Abstract][Full Text] [Related]
62. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
[TBL] [Abstract][Full Text] [Related]
63. Coexpression with the inward rectifier K(+) channel Kir6.1 increases the affinity of the vascular sulfonylurea receptor SUR2B for glibenclamide.
Russ U; Hambrock A; Artunc F; Löffler-Walz C; Horio Y; Kurachi Y; Quast U
Mol Pharmacol; 1999 Nov; 56(5):955-61. PubMed ID: 10531400
[TBL] [Abstract][Full Text] [Related]
64. A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor.
Mikhailova EA; Ashcroft SJ; Mikhailov MV
Anal Biochem; 2002 Aug; 307(2):383-5. PubMed ID: 12202259
[No Abstract] [Full Text] [Related]
65. Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte.
Tanemoto M; Vanoye CG; Dong K; Welch R; Abe T; Hebert SC; Xu JZ
Am J Physiol Renal Physiol; 2000 Apr; 278(4):F659-66. PubMed ID: 10751228
[TBL] [Abstract][Full Text] [Related]
66. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
[TBL] [Abstract][Full Text] [Related]
67. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide.
Ohnota H; Koizumi T; Tsutsumi N; Kobayashi M; Inoue S; Sato F
J Pharmacol Exp Ther; 1994 May; 269(2):489-95. PubMed ID: 8182516
[TBL] [Abstract][Full Text] [Related]
68. Effective treatment of diabetes caused by activating ABCC8/SUR1 mutation with glimepiride.
Karges B; Schnur D; Ellard S; Kentrup H; Karges W
Diabet Med; 2012 May; 29(5):692-3. PubMed ID: 21992555
[No Abstract] [Full Text] [Related]
69. Characterization of the sulfonylurea receptor on beta cell membranes.
Gaines KL; Hamilton S; Boyd AE
J Biol Chem; 1988 Feb; 263(6):2589-92. PubMed ID: 3125168
[TBL] [Abstract][Full Text] [Related]
70. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
Simpson SH; Lee J; Choi S; Vandermeer B; Abdelmoneim AS; Featherstone TR
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
[TBL] [Abstract][Full Text] [Related]
71. [Pharmacogenetics of insulin secretagogue antidiabetics].
Winkler G; Gerô L
Orv Hetil; 2011 Oct; 152(41):1651-60. PubMed ID: 21959939
[TBL] [Abstract][Full Text] [Related]
72. [Mitiglinide (KAD-1229)].
Kusama H; Shibata N
Nihon Rinsho; 2002 Sep; 60 Suppl 9():559-65. PubMed ID: 12387051
[No Abstract] [Full Text] [Related]
73. Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels.
Ashcroft FM; Gribble FM
J Diabetes Complications; 2000; 14(4):192-6. PubMed ID: 11004427
[TBL] [Abstract][Full Text] [Related]
74. [Molecular mechanisms of insulin secretion].
Bataille D
Diabetes Metab; 2002 Dec; 28(6 Suppl):4S7-13. PubMed ID: 12703060
[TBL] [Abstract][Full Text] [Related]
75. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
76. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
[TBL] [Abstract][Full Text] [Related]
77. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin.
Monami M; Luzzi C; Lamanna C; Chiasserini V; Addante F; Desideri CM; Masotti G; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2006; 22(6):477-82. PubMed ID: 16634115
[TBL] [Abstract][Full Text] [Related]
78. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration.
Engler RL; Yellon DM
Circulation; 1996 Nov; 94(9):2297-301. PubMed ID: 8901685
[No Abstract] [Full Text] [Related]
79. Rates of hypoglycemia in users of sulfonylureas.
van Staa T; Abenhaim L; Monette J
J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
[TBL] [Abstract][Full Text] [Related]
80. Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion.
Simard JM; Kilbourne M; Tsymbalyuk O; Tosun C; Caridi J; Ivanova S; Keledjian K; Bochicchio G; Gerzanich V
J Neurotrauma; 2009 Dec; 26(12):2257-67. PubMed ID: 19604096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
